Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.
Authors
Tomoki Sakakida
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Tomoki Sakakida , Toshiki Masuishi , Yasunobu Ishizuka , Munehiro Wakabayashi , Hiroyuki Kodama , Yukiya Narita , Kazunori Honda , Hiroya Taniguchi , Shigenori Kadowaki , Masashi Ando , Koji Komori , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 132)
DOI
10.1200/JCO.2024.42.3_suppl.132
Abstract #
132
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of CAPOXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSGO).
First Author: Yoshinori Kagawa
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
First Author: Jin Won Kim
Poster
2020 Gastrointestinal Cancers Symposium
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
First Author: Harry H. Yoon
Poster
2020 Gastrointestinal Cancers Symposium
Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy.
First Author: Ying Liu